Shree Ganesh Biotech India Stock Hits All-Time Low Amidst Prolonged Downtrend

Price Movement and Market Context

On 21 Nov 2025, Shree Ganesh Biotech India’s share price touched Rs.0.65, establishing a fresh 52-week and all-time low. This level is notably below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. The stock’s one-day performance registered a decline of 1.49%, compared with the Sensex’s marginal fall of 0.10% on the same day.

Examining the short to medium term, the stock’s weekly return stands at -5.71%, while the Sensex recorded a positive 1.16% over the same period. Monthly and quarterly returns for Shree Ganesh Biotech India are -13.16% and -15.38% respectively, contrasting with the Sensex’s gains of 1.32% and 4.32%. These figures highlight a divergence from broader market trends and sector performance.

Long-Term Performance Trends

Over the past year, the stock has recorded a decline of 36.54%, whereas the Sensex has advanced by 10.87%. Year-to-date figures mirror this trend, with Shree Ganesh Biotech India down 36.54% against the Sensex’s 9.48% rise. The three-year performance shows a more pronounced gap: the stock is down 63.93%, while the Sensex has appreciated by 39.90%. Over five years, the stock’s value has contracted by 86.85%, in stark contrast to the Sensex’s near doubling with a 94.94% increase. The ten-year performance remains flat for the stock, whereas the Sensex has surged by 230.68%.

Financial Health and Profitability Indicators

Shree Ganesh Biotech India’s financial metrics reveal ongoing difficulties. The company reported net sales of Rs.5.16 crores for the nine months ending September 2025, representing a contraction of 44.64% compared to the previous period. Correspondingly, the profit after tax (PAT) for the same period was a loss of Rs.0.61 crores, also reflecting a 44.64% decline.

The company’s ability to manage its debt obligations is under pressure, with an average EBIT to interest ratio of 0.91, indicating that earnings before interest and tax are insufficient to comfortably cover interest expenses. This ratio suggests a constrained capacity to service debt from operating profits.

Return on equity (ROE) averages at 2.62%, signalling limited profitability generated from shareholders’ funds. Additionally, the debtors turnover ratio for the half-year period stands at 0.00 times, pointing to challenges in realising receivables efficiently.

Valuation and Risk Considerations

The stock’s valuation appears elevated relative to its historical averages, contributing to a perception of increased risk. Over the past year, while the stock’s return was approximately -35.58%, profits have contracted by 86.6%, underscoring the disparity between market price and earnings performance.

Majority shareholding remains with non-institutional investors, which may influence liquidity and trading dynamics. The stock’s performance relative to the Pharmaceuticals & Biotechnology sector has been subdued, with the sector generally maintaining steadier returns.

Summary of Current Position

Shree Ganesh Biotech India’s stock has reached a historic low, reflecting a prolonged period of subdued financial performance and market valuation pressures. The company’s sales and profitability metrics indicate contraction, while its capacity to service debt remains limited. The stock’s relative underperformance against the Sensex and sector benchmarks highlights the challenges faced within its industry segment.

Investors and market participants observing this stock will note the significant gap between its current market price and historical performance levels, as well as the ongoing financial constraints evident in recent results.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →